Using fewer—but higher—doses of radiation to treat men with prostate cancer who had their prostates removed does not increase long-term side effects or lower their quality of life compared to conventional radiation treatment, a multi-institutional clinical trial showed.
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
